Hematopoietic stem cell transplant (HSCT) recipients are uniquely threatened by the emergence of multidrug-resistant (MDR) bacteria because these patients rely on im- 
| INTRODUCTION
Hematopoietic stem cell transplant (HSCT) recipients are at high risk of bacteremia early after transplantation because of two major insults to their innate immune system. First, these patients have prolonged neutropenia after receipt of their conditioning regimen and thus lack the first and most important phagocytes to combat bacterial infections. 1, 2 Second, their conditioning regimen leads to marked gastrointestinal (GI) mucositis, and thus the integrity of their mucosal barrier is damaged. These two key insults establish a high-risk setting for bacteremia caused by enteric organisms and for severe complications from these infections.
Before the 1960s, empirical antibacterial therapy was not routinely administered to febrile neutropenic patients. This strategy of delaying therapy until culture results were available was associated with poor outcomes in neutropenic patients with gram-negative bacteremia.
For example, bacteremia caused by Pseudomonas aeruginosa carried a 60%-80% mortality rate in this era. 3, 4 These outcomes improved dramatically after a critical change in practice to administer antibacterial agents with in vitro activity against prominent gram-negative bacteria to neutropenic patients immediately for fever or at the first sign of infection.
4-6
Current recommendations for the management of fever and neutropenia in oncology patients are to administer antimicrobial agents that are active against the three most common causes of gram-negative bacteremia in neutropenic patients: Escherichia coli, Klebsiella pneumoniae, and P. aeruginosa. [7] [8] [9] Recommended agents include ceftazidime, cefepime, piperacillin-tazobactam, or a carbapenem as monotherapy, based on results from randomized clinical trials that were conducted over a decade ago. [10] [11] [12] [13] [14] However, over the last decade, multidrugresistant (MDR) Enterobacteriaceae and P. aeruginosa have become increasingly prevalent among hospitalized patients. 15, 16 Furthermore, vancomycin-resistant Enterococcus has increasingly been reported as a common cause of bacteremia in HSCT recipients. 17, 18 This increase in resistance among the most common causes of bacteremia in neutropenic patients and HSCT recipients threatens the applicability of currently used algorithms.
The objective of this review was to delineate the current epidemiology and treatment considerations for three of the most challenging bacterial pathogens in HSCT recipients: MDR Enterobacteriaceae, including extended-spectrum β-lactamase (ESBL) and carbapenemase
producers, P. aeruginosa, and vancomycin-resistant Enterococcus (VRE).
We also discuss strategies to curb the threat posed by these pathogens, including an evaluation of preventative measures and strategies to minimize delays in administration of appropriate therapies for infected patients.
| ESBL-PRODUCING ENTEROBACTERIACEAE (ESBL-E)

| Epidemiology
ESBLs are enzymes that are capable of hydrolyzing penicillins, monobactams, and extended-spectrum cephalosporins. 19 Multiple reports from oncology centers in North America, Europe, and Asia have identified ESBL prevalence rates of 17%-37% among bloodstream isolates of Enterobacteriaceae from patients with hematologic malignancies (Table 1 9,20-26 ). Not only did these reports demonstrate a high prevalence of ESBL-E in this population, but many also reported higher mortality rates associated with ESBL-E bacteremia compared to bacteremia caused by non-ESBL-producing Enterobacteriaceae.
For example, in a study of 14 Italian hematologic oncology centers, the 21-day mortality rate was 26% after bacteremia caused by third-generation cephalosporin-resistant Enterobacteriaceae, most of which were likely ESBL-E, compared to 5% after bacteremia caused by third-generation cephalosporin-susceptible Enterobacteriaceae. 9 Furthermore, ESBL-E have expanded their host range into HSCT recipients. In a report from Korea, 44% of E. coli bacteremias in HSCT recipients were ESBL producers and having an HSCT was a risk factor for ESBL-E bacteremia. 24 HSCT centers from Italy and Turkey reported that 18% and 23%, respectively, of E. coli bloodstream isolates and 86% and 22%, respectively, of K. pneumoniae bloodstream isolates were ESBL-producing strains. 20 Third-generation cephalosporin resistance was used as a surrogate for ESBL production in this study.
HSCT, hematopoietic stem cell transplantation; ESBL, extended-spectrum beta-lacatamse; BSI, bloodstream infection; NR, not reported.
2011 to 2016 had a phenotypic profile suggestive of ESBL production (ceftriaxone-resistant, meropenem-susceptible).
| Treatment
The ESBL-E test highly susceptible to carbapenems and these agents are the treatments of choice for serious ESBL-E infections in HSCT recipients. 19 ESBL-E have variable susceptibility to other first-line recommended therapies for fever and neutropenia, with susceptibility rates to ceftazidime, cefepime, and piperacillin-tazobactam of 20%-30%, 60%-70%, and 70%-95%, respectively. Clinical data characterizing the use of cefepime for the treatment of ESBL-E bacteremia substantiate these in vitro concerns. Three cohort studies comparing cefepime to carbapenems for the treatment of ESBL-E bacteremia demonstrated increased mortality with cefepime, including in multivariable and propensity-score matched analyses. [31] [32] [33] Thus, cefepime should be avoided for the treatment of ESBL-E infections in HSCT recipients.
The role of piperacillin-tazobactam for the treatment of ESBL-E infections is unclear, as no randomized clinical trials comparing piperacillin-tazobactam to carbapenems have been completed. Two large multicenter observational studies of patients with ESBL-E bacteremia found that outcomes of patients treated empirically or as targeted therapy with β-lactam/β-lactamase inhibitors were similar to those of patients treated with a carbapenem in multivariable analyses. 34, 35 However, a large single-center cohort study from the United States (U.S.) of patients with ESBL-E bacteremia demonstrated a two-fold increased risk of death in patients who received piperacillin-tazobactam empirically compared to those who received a carbapenem empirically, and this difference persisted in multivariable and propensity score-adjusted analyses. 36 In the first two studies demonstrating the equivalence of piperacillin-tazobactam and carbapenems, two-thirds of the bacteremias originated from the urinary or biliary tracts. Piperacillin-tazobactam may be more effective in these settings because it achieves high urinary and biliary tract concentrations and biliary infections are often treated concurrently with biliary tract decompression. 37 Furthermore, piperacillintazobactam was administered at dosages of 4.5 g every 6 hours or as a prolonged infusion in these studies. Conversely, in the study demonstrating the superiority of carbapenems, the source of the majority of bacteremias was central line-associated or intra-abdominal, and the most common dosage of piperacillin-tazobactam was 3.375 g every 6 hours. In addition, very few neutropenic patients or HSCT recipients were included in these studies. In summarizing results from these studies, it could be concluded that piperacillintazobactam, dosed at either 4.5 g every 6 hours or as a prolonged in- (Table 2   46 ).
Although the global threat of CRE has been well documented, the emergence of CRE in patients with hematologic malignancies and HSCT recipients has only recently been described. 49, 51 Publications reporting at least 10 HSCT recipients with CRE infection are outlined in Table 3 . [52] [53] [54] [55] [56] Carbapenem-resistant K. pneumoniae (CRKP) has become a major cause of bacteremia in this patient population in Italy.
In a prospective cohort study of 13 Italian hematologic oncology centers from 2010 to 2014, 161 (58%) of 278 episodes of K. pneumoniae bloodstream isolates were carbapenem-resistant. 52 In a study of 52
Italian HSCT centers, the overall incidence of post-transplant CRKP infection from 2010 to 2013 was 0.4% after an autologous transplant and 2% after an allogeneic transplant. 54 For comparison, the 12-month cumulative incidence of aspergillosis and candidiasis in HSCT recipients in the Transplant-Associated Infection Surveillance Network was 1.6% and 1.1%, respectively. 57 CRE is also an established pathogen in hematologic oncology centers in NYC. Our center reported that CRE bacteremia occurred in 1.8% of HSCT recipients within 12 months after transplantation. 51 In a study of BSIs in neutropenic patients with hematologic malignancies at two NYC oncology centers, 43 (2.2%) of 1992 BSI episodes were caused by CRE, CRE caused 4.7% of gramnegative bacteremias, and 18% of K. pneumoniae bacteremias were carbapenem-resistant. 55 Not only are CRE emerging causes of bacteremia in HSCT recipients, but also CRE bacteremia is associated with high mortality rates in this population. In fact, both overall and CRE bacteremia-related mortality rates in patients with hematologic malignancies and HSCT recipients are consistently >50% (Table 3) . Trecarichi et al 52 found that the 21-day mortality rate in patients with hematologic malignancies was 53% after CRKP bacteremia, compared to 15% after carbapenemsusceptible K. pneumoniae bacteremia, and carbapenem resistance was independently associated with mortality. A CRKP infectionrelated mortality rate of 64% was reported in allogeneic HSCT (allo-HSCT) recipients.
54
A likely explanation for these high mortality rates is that CRE are resistant to recommended empirical therapies for fever and neutropenia in patients with cancer, 7 and thus appropriate CREactive therapy is delayed until the availability of organism identification and antimicrobial susceptibility testing (AST) results. In HSCT 
| Treatment
Treatment options for CRE infections are extremely limited, as in addition to being resistant to β-lactam agents, CRE are also typically resistant to fluoroquinolones and trimethoprim-sulfamethoxazole. 49 Antimicrobial agents that have typically retained activity against CRE are outlined in Table 4 
77,80
Ceftazidime-avibactam was approved by the U.S. Food and Drug
Administration (FDA) in 2015 and represents the first β-lactam/ β-lactamase inhibitor with activity against KPC-producing CRE (Table 5 83 ,84 ). This agent has demonstrated comparable efficacy to The administration of β-lactam agents as an extended infusion (over hours instead of over 30 minutes) is a strategy has also been shown to decrease the emergence of resistance in P. aeruginosa in in vitro models. 100 Furthermore, extended infusion strategies maintain the time that the concentration of the antibiotic is above the MIC for a longer portion of the dosing interval than standard infusions, and this parameter is correlated with increased bactericidal activity against P. aeruginosa in animal models. 101 Although no randomized controlled trials have been conducted to definitively prove the benefit of this strategy for P. aeruginosa infections, two single-center observational studies demonstrated decreased mortality in critically ill patients with P. aeruginosa infection after switching from standard infusions of piperacillin-tazobactam and cefepime to extended infusions of these agents. 101, 102 These compelling in vitro and observational data provide rationale for using extended infusions of β-lactam agents for the treatment of invasive P. aeruginosa infections in HSCT recipients, provided that venous access is not an issue.
P. aeruginosa that is not susceptible to anti-pseudomonal β-lactam agents or fluoroquinolones has previously been treated with polymyxins or aminoglycosides as agents of last resort.
Unfortunately, these antibiotics have high rates of toxicity and are less effective than β-lactam agents in oncology patients with P. aeruginosa bacteremia. 72, 76 Ceftolozane-tazobactam, an additional new cephalosporin/β-lactamase inhibitor, is a promising alternative for the treatment of these MDR P. aeruginosa infections (Table 5 ).
Approximately two-thirds of P. aeruginosa isolates that are resistant to extended-spectrum cephalosporins, piperacillin-tazobactam, and meropenem test susceptible to this new agent. 103 Ceftazidime-avibactam represents an additional option for MDR P. aeruginosa infections. In addition to having in vitro activity against KPC-producing Enterobacteriaceae, it also has in vitro activity against MDR P. aeruginosa strains that is comparable to that of ceftolozanetazobactam (Table 5) . 107, 108 Preliminary in vivo murine models suggest that the addition of avibactam to ceftazidime enhances bacterial killing of P. aeruginosa infections compared to ceftazidime alone. 109 As with ceftolozane-tazobactam, additional pre-clinical and clinical data are urgently needed to better understand the role of this new agent for MDR P. aeruginosa infections.
| VRE
| Epidemiology
VRE is increasingly recognized as a major pathogen in HSCT recipients. In fact, some centers have reported that VRE is the most common cause of bacteremia early after allogeneic transplantation.
17,18
The reported cumulative incidence of post-transplant VRE bacteremia in allo-HSCT recipients at U.S. centers is 6%-16%. 17, 18, 110, 111 VRE bacteremia in this population typically occurs in the setting of broadspectrum antimicrobial exposures during the neutropenic period, which leads to an absence of normal enteric bacteria and intestinal domination with VRE.
18,112
VRE bacteremia after allogeneic transplantation has significant consequences. Although VRE is typically considered to be a relatively avirulent pathogen, 113 it sometimes causes bacteremia and septic shock in neutropenic HSCT recipients. 17, 18, 114 At our center, we found that VRE bacteremia led to septic shock and 7-day mortality at rates comparable to those observed after gram-negative bacteremia.
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Post-transplant VRE bacteremia has also been independently associated with increased mortality. 110, 111 However, whether this increased mortality is directly attributable to VRE infection or a marker for a complicated post-transplant course is unclear.
| Treatment
In addition to vancomycin resistance, VRE are typically resistant to all β-lactam agents, leaving few available treatment options. 113 Daptomycin and linezolid are most commonly used for the treatment of invasive VRE infections, although only linezolid has U.S. FDA approval for this indication. No randomized clinical trials compare the efficacy of these two agents for the treatment of VRE bacteremia, and observational studies have provided conflicting results as to which agent is superior. 115, 116 Daptomycin is often preferred to linezolid for VRE bacteremia in HSCT recipients because it has bactericidal activity and a favorable safety profile. In contrast, linezolid is bacteriostatic, myelosuppressive, and associated with a slight delay in neutrophil recovery in oncology patients. 117 Daptomycin is not an effective therapy for pneumonia because it is inactivated by alveolar surfactants.
118
Furthermore, daptomycin resistance in VRE has been increasingly reported, 119 particularly in patients with hematologic malignancies. One major cancer center reported that 15% of their VRE bloodstream isolates were daptomycin-non-susceptible. 120 Moreover, a recent multicenter study of Enterococcus faecium bacteremia, which included many HSCT recipients and neutropenic patients, questioned whether the current CLSI susceptible breakpoint of ≤4 μg/mL for daptomycin is too high, implying an underreporting of daptomycin resistance. 121 They found that patients with have demonstrated decreased mortality after VRE bacteremia with dosages of ≥9 mg/kg and ≥10 mg/kg, respectively, compared to lower doses. [122] [123] [124] [125] Some experts recommend using daptomycin in combination with β-lactam agents (eg, ampicillin or ceftaroline) for VRE infections with elevated daptomycin MICs, as these combinations demonstrate marked in vitro synergy. 126 Weekly monitoring of serum creatinine phosphokinase levels is recommended during daptomycin therapy, as almost 3% of patients receiving daptomycin in clinical trials developed elevated creatinine phosphokinase levels.
127
Other agents with in vitro activity against VRE include quinupristindalfopristin, tigecycline, tedizolid, oritavancin, and telavancin.
128
Quinupristin-dalfopristin is rarely used because of high rates of adverse effects that lead to treatment discontinuation in nearly 20% of patients. 129 Tigecycline has major limitations as outlined in Table 4 , and sparse clinical data support the use of these alternative agents for VRE bacteremia. Tedizolid is a new oxazolidinone that appears to be less myelosuppressive than linezolid, 130 and thus is an attractive candidate for use in HSCT recipients. However, animal models have demonstrated that the efficacy of tedizolid is markedly reduced in the setting of neutropenia, 130 thus making it a less attractive alternative for VRE infections in neutropenic patients. Oritavancin may be an option for linezolid-and daptomycin-non-susceptible VRE infections, but in vivo and clinical data are extremely limited.
| PREVENTION OF MDR BACTERIAL INFECTIONS IN HSCT RECIPIENTS
| Prevention of transmission of MDR pathogens
The limited antimicrobial armamentarium against MDR Enterobacteriaceae, P. aeruginosa, and VRE, and the poor outcomes 
| GI screening for implementation of contact precautions and targeted decolonization
Active surveillance, where HSCT recipients are screened for colonization with MDR gram-negative bacteria and VRE, can be utilized to implement multiple interventions. First, patients who are found to be colonized with an MDR pathogen can be placed on contact precautions, which may decrease the inpatient transmission of these organisms. Although this approach has led to reductions in CRE infection rates in certain settings, 136 data are sparse to indicate that this intervention decreases the nosocomial transmission of ESBL-E, P. aeruginosa, or VRE. In fact, a recent article demonstrated that discontinuation of a program of active surveillance for VRE and contact isolation of colonized patients had no effect on the incidence of VRE infection in a hematologic oncology unit.
137
Active surveillance can also be used to identify colonized patients who may be candidates for targeted decolonization strategies. Decolonization has primarily been evaluated using oral aminoglycosides and/or colistin to prevent ESBL-E and CRE infections in colonized patients. Although decolonization may reduce carriage of these organisms during therapy, this reduction is generally short-lived and can lead to resistance to the agents that are used. 
| ADDITIONAL STRATEGIES TO IMPROVE OUTCOMES OF INFECTED PATIENTS
| GI screening as a guide for empirical antibacterial therapy
The emergence of MDR Enterobacteriaceae, P. aeruginosa, and ESBL-E bacteremia during admission for chemotherapy. 142, 143 At our center, we found that 6 of 13 allo-HSCT recipients who were colonized with ESBL-E on admission for transplantation developed ESBL-E bacteremia during neutropenia, compared to none of 118 patients who were not colonized (P < .001). 144 A multicenter study of HSCT recipients in Italy also identified high rates of GI colonization leading to infection with CRKP. CRKP infection occurred after transplantation in 26% of colonized autologous HSCT recipients and 39% of colonized allo-HSCT recipients.
54
These data suggest that screening for GI colonization with MDR Enterobacteriaceae may be a useful tool to identify HSCT recipients who are at high risk of developing subsequent infection caused by these organisms, and who may benefit from an adjustment of their empirical therapy to cover for these pathogens. However, prospec- 
| Rapid identification of bloodstream pathogens
An additional strategy to improve the outcomes of HSCT recipients Nanosphere, Northbrook, IL, USA) detect enterococci, the most common Enterobacteriaceae, and P. aeruginosa, in addition to other prominent bloodstream pathogens. [148] [149] [150] It is important to note that both systems detect the vanA and vanB genes, which confer vancomycin resistance in enterococci, and bla KPC , the most common gene that confers carbapenem resistance in Enterobacteriaceae in the U.S. and many other countries. In addition, the Verigene system detects genes that encode other carbapenemases and the most common ESBL, CTX-M.
Implementation of one of these systems should decrease the time to identification of MDR Enterobacteriaceae, P. aeruginosa, and VRE from 24-72 hours after culture positivity to only 2 hours after culture positivity. This improved speed of detection should lead to more timely therapy for infections caused by these bacteria, which will hopefully improve outcomes. However, it should be noted that these assays do not provide information to predict antimicrobial suscepti- 
| Management of infected central venous catheters (CVCs)
Bacteremia caused by MDR Enterobacteriaceae and VRE in HSCT recipients is most commonly from GI translocation during chemotherapy-induced neutropenia. 7, 112, 144 However, CVCs are occasionally the sources of bacteremia caused by these organisms. P. aeruginosa is less likely to originate from the GI tract than VRE and MDR Enterobacteriaceae and is more likely to cause CVC-related bacteremias. 7, 145 If blood cultures are collected from a peripheral vein and a CVC simultaneously, then culture positivity that occurs 2 hours earlier in the CVC culture compared to the peripheral culture is suggestive that the catheter is the source of the infection. 152 Catheter removal is imperative for all CVC-related infections that involve the tunnel track or port pocket site or in the setting of hemodynamic instability. 153 In cases of CVC-related bacteremias in hemodynamically stable patients that do not involve a tunnel track or port pocket site, CVC retention can be considered, particularly in patients with refractory thrombocytopenia or lack of alternate intravenous access. If the CVC is retained, antimicrobial therapy should be administered through the infected catheter, potentially in combination with antibiotic lock therapy. 
| CONCLUSIONS
In summary, MDR Enterobacteriaceae, P. aeruginosa, and VRE are becoming increasingly common bloodstream pathogens in HSCT recipients and outcomes of patients infected with these bacteria are worse than those of patients infected with more susceptible bacteria.
Developing preclinical and clinical research data to guide the use of new antimicrobial agents for the treatment of these pathogens in the HSCT population is paramount. Identification of optimal strategies to prevent these infections is also an urgent need. Screening for GI colonization to guide empirical therapy and using rapid diagnostics may be approaches that lead to improved outcomes for infected HSCT recipients.
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